SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 2, 1997
----------------
HemaSure Inc.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 0-19410 04-3216862
- ---------------------------- ------------------ -----------------------
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) file number) Identification No.)
140 Locke Drive, Marlborough, Massachusetts 01752
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (508) 485-6850
-----------------------------
Not Applicable
- -------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
<PAGE>
Item 5. Other Events.
On April 2, 1997, Timothy J. Barberich was elected by the Board of
Directors of HemaSure Inc. (the "Company") to serve as Chairman of the Company.
Mr. Barberich has served as a director of the Company since its organization in
1993 and serves as President, Chief Executive Officer and a director of Sepracor
Inc., a specialty pharmaceutical company. In addition, Eugene J. Zurlo (the
former Chairman of the Company), Steven H. Rouhandeh (the former President and
Chief Executive Officer of the Company), Edward W. Kelly (the former Executive
Vice President and Chief Operating Officer of the Company), and Jeffrey B. Davis
(the former Senior Vice President and Chief Financial Officer of the Company)
were relieved of their duties as officers and employees of the Company. The need
to reduce G&A expense as the Company exited the plasma business and the desire
to focus management resources on the Company's core business of leukoreduction
and viral inactiviation technologies were the primary reasons for the
dismissals.
The Board of Directors of the Company thereafter appointed John F.
McGuire, the former Vice President and General Manager of Johnson & Johnson's
("J&J") Ortho Diagnostic Systems' Blood Bank Business Unit, to serve as Chief
Executive Officer, President and a director of the Company. Mr. McGuire has been
employed at J&J since 1988 and has held the positions of Marketing Director for
the AIDS and Hepatitis Business Unit; Managing Director of Ortho Diagnostic
Systems, United Kingdom and Belgium; Vice President, Sales and Marketing, North
America; and most recently, Vice President and General Manager of Ortho
Diagnostic Systems Blood Bank Business Unit. From 1977 to 1988, Mr. McGuire held
various positions at E.I. DuPont De Nemours & Company, the last of which was
National Sales Manager, AIDS and Hepatitis Business.
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
HEMASURE INC.
(Registrant)
Date: April 16, 1997 By: /s/ James B. Murphy
------------------------
Name: James B. Murphy
Title: Senior Vice President
Finance and Administration
3
